BusinessARCA Biopharma announces first quarter 2018 financial results AND Provides Corporate UpdateBy Nasdaq OMXMay 8, 2018, 8:15 PM UTC
BusinessARCA biopharma Reports Topline Phase 2B Results for GENETIC-AF Clinical TrialBy Nasdaq OMXFeb 26, 2018, 1:00 PM UTC
BusinessARCA biopharma Announces Completion of GENETIC-AF Phase 2B Clinical TrialBy Nasdaq OMXJan 8, 2018, 1:31 PM UTC
BusinessARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic TargetingBy Nasdaq OMXNov 16, 2017, 1:30 PM UTC
BusinessARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim AnalysisBy Nasdaq OMXAug 9, 2017, 8:30 PM UTC
BusinessARCA Biopharma Announces Database Lock for GENETIC-AF Phase 2B Interim Efficacy Analysis – DSMB Recommendation Anticipated in August 2017By Nasdaq OMXJun 20, 2017, 12:30 PM UTC
BusinessARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business UpdateBy Nasdaq OMXMay 15, 2017, 12:32 PM UTC
BusinessARCA Biopharma Announces First Quarter 2017 Financial Results and Provides Business UpdateBy Nasdaq OMXMay 15, 2017, 12:32 PM UTC
